Walleye Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Walleye Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,455	Closed	-$467K	–	4997
2023 Q1	$467K	Buy	16,455 +5,623	+52%	+$167K	0.01%	1774
2022 Q4	$317K	Buy	+10,832	New	+$344K	0.01%	1746
2022 Q2	–	Sell	-8,576	Closed	-$424K	–	2778
2022 Q1	$424K	Buy	+8,576	New	+$412K	0.01%	1102
2020 Q1	–	Sell	-224	Closed	-$13K	–	1820
2019 Q4	$13K	Sell	224 -736	-77%	-$43.9K	﹤0.01%	1637
2019 Q3	$54K	Buy	960 +516	+116%	+$29K	﹤0.01%	1591
2019 Q2	$25K	Buy	444 +344	+344%	+$17.9K	﹤0.01%	1501
2019 Q1	$5K	Buy	+100	New	+$4.45K	﹤0.01%	1447

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's EGRX Position: Q2 2023 in Review

Walleye Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 16,455 shares — an estimated $467K sold.

Walleye Capital first reported a position in EGRX in Q1 2019 and held it in 7 quarters. The position peaked at $467K in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

Walleye Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 16,455 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $467K.
Walleye Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 7 quarters.
Walleye Capital's Eagle Pharmaceuticals, Inc. position peaked at $467K in Q1 2023.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.